An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICTirzepatide
Weight ManagementAppetiteGlucose / Insulin
Status
Approved
Related
4
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYNew England Journal of Medicine, 2022Verified 2026-09-13
Tirzepatide activates GIP and GLP-1 receptors. Its human evidence base includes large randomized trials; indication and product-label context must remain distinct from compounded or research products.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Semaglutide
An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
02PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Cagrilintide
An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.
Weight ManagementAppetiteFat Loss
04PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.